Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia

Leuk Lymphoma. 2021 Nov;62(11):2812-2814. doi: 10.1080/10428194.2021.1929959. Epub 2021 May 25.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Intramural

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Bacterial Toxins* / therapeutic use
  • Exotoxins / therapeutic use
  • Humans
  • Leukemia, Hairy Cell* / drug therapy
  • Recurrence

Substances

  • Antineoplastic Agents
  • Bacterial Toxins
  • Exotoxins
  • immunotoxin HA22